Related Experiment Video
Updated: Feb 15, 2026

Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia
Published on: February 17, 2023
Effect of MDR1 C1236T polymorphism on cyclosporine pharmacokinetics: A systematic review and meta-analysis
Zhe Chen1, Lingli Zhang, Chunsong Yang
1Department of Pharmacy, West China Second University Hospital, Sichuan University, Chengdu, Sichuan Evidence-Based Pharmacy Center, West China Second University Hospital, Sichuan University, Chengdu, Sichuan Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Chengdu, Sichuan West China School of Pharmacy, Sichuan University, Chengdu, Sichuan, China.
Insights
The MDR1 C1236T polymorphism may slightly impact cyclosporine pharmacokinetics. This meta-analysis found minor effects on drug concentrations in transplantation patients, influencing trough blood concentration (C0) and 2-hour levels (C2).
Area of Science:
- Pharmacogenomics
- Drug Metabolism
- Immunosuppression
Background:
- Cyclosporine (CsA) pharmacokinetics exhibit significant inter-individual variability.
- Conflicting data exist regarding the influence of MDR1 exon 12 SNP C1236T on CsA pharmacokinetics.
- This meta-analysis aims to clarify the association between MDR1 C1236T polymorphism and CsA pharmacokinetics.
Purpose of the Study:
- To investigate the effect of the MDR1 C1236T single nucleotide polymorphism (SNP) on cyclosporine pharmacokinetics.
- To resolve conflicting findings in existing literature regarding this genetic association.
- To provide a comprehensive analysis of SNP C1236T's impact on CsA drug levels.
Main Methods:
- A systematic literature search was performed across multiple databases (PubMed, Embase, Cochrane Library, CNKI, Wan Fang, CBM, VIP) up to January 2017.
- Pharmacokinetic parameters including C0, C2, Cmax, and daily dose were extracted from eligible studies.
- A meta-analysis was conducted using RevMan 5.3 software to synthesize the data.
Main Results:
- Eleven studies encompassing 1361 individuals were included in the meta-analysis.
- Significant differences in dose-adjusted C0 were observed between CC and TT genotypes (P=.02).
- Significant differences in C2 levels were found between CC and CT genotypes (P=.03), and between CC and TT genotypes (P=.03).
- No major influence was detected on Cmax, daily dose, or C0 (unadjusted).
Conclusions:
- The MDR1 C1236T polymorphism appears to have a minor effect on cyclosporine pharmacokinetics.
- This genetic variation may influence specific pharmacokinetic parameters like C0 and C2 in transplantation patients.
- Further research may be warranted to fully elucidate the clinical significance of this SNP in CsA therapy.
Background:
Cyclosporine (CsA) is one of the immunosuppressive drugs, whose pharmacokinetic characteristics vary greatly among individuals. The published data reveal conflicting effects of the polymorphism of MDR1 exon 12 SNP C1236T on the pharmacokinetics of cyclosporine.This study aims to conduct a meta-analysis to investigate the effect of SNP C1236T on the pharmacokinetics of cyclosporine.
Methods:
A literature retrieval was conducted to find the relevant papers in databases including PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure (CNKI), Wan Fang Database (Wan Fang), Chinese Biomedical Literature Database (CBM), VIP Database for Chinese Technical Periodicals (VIP) electronic source for published studies until January 2017. The pharmacokinetic parameters, including C0 (trough blood concentration), C2 (whole-blood levels at 2 hours after drug intake), Cmax (the maximum concentration), and daily dose were extracted and a meta-analysis was performed by RevMan 5.3.
Results:
A total of 11 papers concerning 1361 individuals were included in the meta-analysis. As for dose adjusted C0, the results showed difference between subjects carrying CC genotypes and TT genotypes (MD: 6.76, 95% CI [2.38, 11.14], P = .02]. As for C2, the results showed significant difference between subjects carrying CC genotypes and CT genotypes (MD: -18.50, 95% CI [-35.49, -1.52], P = .03), as well as CC genotypes and TT genotypes (MD: -19.01, 95% CI (-35.85, -2.16), P = .03). As for Cmax, daily dose, and C0, the overall results showed no major influence.
Conclusions:
MDR1 C1236T polymorphism may have a minor effect on cyclosporine pharmacokinetics in transplantation patients.
More Related Videos
08:36Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
Published on: April 19, 2024
06:26Meta-analysis of Voxel-Based Neuroimaging Studies using Seed-based d Mapping with Permutation of Subject Images SDM-PSI
Published on: November 27, 2019
Related Concept Videos
Analysis of Population Pharmacokinetic Data
Noncompartmental Analysis: Miscellaneous Pharmacokinetic Parameters
One key aspect of the noncompartmental approach is determining a drug's total clearance. This can be done by dividing the drug dose by the area under the concentration-time curve from zero to infinity. The area under the concentration-time curve represents the drug's...
Review and Preview
Percentiles are a type of fractile that partition data into...
Review and Preview
Random and Systematic Errors
Directing Effect of Substituents: meta-Directing Groups